Biography

et.photo

Edward Tobinick M.D. Scientific Biography

Edward Lewis Tobinick, M.D. is an American physician, inventor, and scientist.  He has authored multiple, peer-reviewed, scientific publications in the field of neurology and granted more than 30 U.S. and international patents for his medical inventions. His work has been cited by more than 3000 scientific publications. His inventions include novel methods of drug delivery to selectively enhance the ability of large molecular weight drugs and biologics to reach the brain in therapeutic concentration. His medical discoveries have contributed to our fundamental understanding of brain and neuronal function in health and disease.

Notably, Dr. Tobinick invented and has refined methods of perispinal delivery of etanercept for therapeutic use in neurology, novel inventions validated by a 2020 randomized, double-blind placebo-controlled clinical trial(1). The randomized trial documented “… rapid and wide-ranging benefits achievable by treating stroke patients with perispinal etanercept,” findings supported by and originally reported in observational studies published by Dr. Tobinick and his colleagues beginning in 2011 (see below).  In 2018 the Australian government designated funds specifically to run an additional randomized, controlled trial of perispinal etanercept for stroke in Australia.

Dr. Tobinick graduated Phi Beta Kappa and Magna Cum Laude with honors in biology from Brandeis University in Waltham, Massachusetts, received his M.D. from the University of California San Diego School of Medicine in La Jolla, California, and completed residency training at UCLA. While in private practice in Beverly Hills and at 100 UCLA Medical Plaza, he also taught medical students, interns, residents and medical faculty as a clinical professor at UCLA for more than 20 years. He founded the Institute of Neurological Recovery in Los Angeles in 2001 and Boca Raton, Florida in 2011. He has been an invited expert reviewer for the journals Brain Research, Clinical Drug Investigation, CNS DrugsCurrent Alzheimer Research, Drug Discovery Today, Experimental NeurologyFuture NeurologyJournal of NeurochemistryJournal of Neuroimmunology, Neuroscience, and Pharmaceutical Medicine and a member of the Editorial Board of the Journal of Neuroinflammation.

Dr. Tobinick has presented his scientific findings regarding perispinal etanercept (PSE) in neurology at multiple U.S. and international medical conferences, including the Alzheimer’s Drug Discovery Conference in New York in 2006; the Karolinska Institute in Stockholm in 2006; the Drug Repositioning Summit in Boston in 2008; the International Conference on Alzheimer’s Disease in Chicago in 2008; the Advances in Alzheimer’s Disease Management conference at the University of Arkansas Medical Sciences in Little Rock in 2008; and, in 2009, the 3rd International Restauracion Neurologica Conference in Havana, the World Pharmaceutical Congress in Philadelphia and the 5th Modern Drug Discovery Conference in San Diego. He has performed collaborative research with physicians and scientists at multiple academic centers, including Stanford University School of Medicine. Further randomized trials of PSE for stroke are in development, with the goal to achieve regulatory approval for perispinal etanercept to help individuals recover from stroke, even years after the acute event.

Download a copy of Dr Tobinick’s 2016 Curriculum Vitae PDF Here.

  1. Phase I/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation.  Expert Opin Investig Drugs, 2020: p. 1-16.

Selected Scientific Publications Authored by Dr. Tobinick: